Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 56 Lung Neoplasms 29 Triple Negative Breast Neoplasms 13 Breast Neoplasms 13 Ovarian Neoplasms 12 Endometrial Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 11 Small Cell Lung Carcinoma 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Neoplasms 10 Fallopian Tube Neoplasms 10 Neoplasm Metastasis 8 Colorectal Neoplasms 5 Adenocarcinoma of Lung 5 Carcinoma 4 Pancreatic Neoplasms 3 Oropharyngeal Neoplasms 3 Melanoma 3 Lung Diseases 3 Esophageal Neoplasms 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Thoracic Neoplasms 2 Sarcoma 2 Respiratory Tract Neoplasms 2 Respiratory Tract Diseases 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Pathologic Complete Response 2 Non-squamous Non-small Cell Lung Cancer 2

Interventions

pembrolizumab 1 erdafitinib 1 enfortumab vedotin 1 Midazolam 1 Metformin 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × Carboplatin × 30 days × Clear all

NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡